Uterine carcinosarcoma

Clinical Obstetrics and Gynecology

Volumn 54, Issue 2, 2011, Pages 292-304

  El Nashar, Sherif A ^a   Mariani, Andrea ^a  

^a MAYO CLINIC   (United States)

Author keywords

cancer; Carcinosarcoma; chemotherapy; radiotherapy; uterus

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CONTRACEPTIVE AGENT; CYCLOOXYGENASE 2; CYTOKERATIN ANTIBODY; DESMIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; GEMCITABINE; IFOSFAMIDE; IMATINIB; K RAS PROTEIN; MESNA; MYOD1 PROTEIN; MYOGLOBIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; PROTEIN S 100; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB; VASCULOTROPIN; VIMENTIN;

ABDOMINAL HYSTERECTOMY; ABDOMINAL MASS; ABDOMINAL PAIN; ADENOSARCOMA; ADJUVANT THERAPY; ADVANCED CANCER; AGE; ANTIANGIOGENIC THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CHEMORADIOTHERAPY; CHONDROSARCOMA; CHROMOSOME ABERRATION; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOLOGY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; ECHOGRAPHY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; EPITHELIUM CELL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GENE MUTATION; GENETIC PREDISPOSITION; HEMORRHAGIC CYSTITIS; HETEROZYGOSITY LOSS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MESENCHYMOMA; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OMENTECTOMY; OMENTUM; ONCOGENE C KIT; OSTEOSARCOMA; OVARY METASTASIS; PATIENT MONITORING; PERITONEUM METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; RHABDOMYOSARCOMA; SALPINGOOOPHORECTOMY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THERAPY DELAY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR BLEEDING; TUMOR DIFFERENTIATION; TUMOR EMBOLISM; UNDIFFERENTIATED CARCINOMA; UTERINE TUBE; UTERUS; UTERUS CARCINOMA; UTERUS CARCINOSARCOMA; UTERUS SARCOMA; VAGINA BLEEDING; VAGINA DISCHARGE;

ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RADIOTHERAPY, ADJUVANT;

EID: 79955570393     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31821ac635     Document Type: Article

References (32)

1. Gonzalez Bosquet J, Terstriep SA, Cliby WA, et al. The impact of multimodal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010; 116:419-423.
2. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer. 1993;71: 1702-1709. (Pubitemid 23056094)
3. Bansal N, Herzog TJ, Seshan VE, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol. 2008; 112:64-70.
4. Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004;58:786-796. (Pubitemid 38221136)
5. Greer BE, Koh WJ, Abu-Rustum N, et al. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009;7:498-531.
6. Nemani D, Mitra N, Guo M, et al. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111:82-88.
7. Chi DS, Mychalczak B, Saigo PE, et al. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997;65:493-498. (Pubitemid 27255994)
8. Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998;68:8-13. (Pubitemid 28109815)
9. Molpus KL, Redlin-Frazier S, Reed G, et al. Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors. Eur J Gynaecol Oncol. 1998;19: 541-546. (Pubitemid 29008294)
10. Chauveinc L, Deniaud E, Plancher C, et al. Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments. Gynecol Oncol. 1999; 72:232-237. (Pubitemid 29093780)
11. Knocke TH, Weitmann HD, Kucera H, et al. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol. 1999;73:389-395. (Pubitemid 29272860)
12. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol. 2001;27: 282-285. (Pubitemid 32621754)
13. Manolitsas TP, Wain GV, Williams KE, et al. Multimodality therapy for patients with clinical Stage I and II malignant mixed Mullerian tumors of the uterus. Cancer. 2001;91:1437-1443. (Pubitemid 32319253)
14. Dusenbery KE, Potish RA, Judson PI. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol. 2004;94:191-196. (Pubitemid 38950519)
15. Menczer J, Levy T, Piura B, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005;97: 166-170. (Pubitemid 40403689)
16. Dusenbery KE, Potish RA, Argenta PA, et al. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol-Cancer Clin Trials. 2005;28:295-300. (Pubitemid 40800483)
17. Villena-Heinsen C, Diesing D, Fischer D, et al. Carcinosarcomas-a retrospective analysis of 21 patients. Anticancer Res. 2006;26:4817-4823.
18. Wong L, See HT, Khoo-Tan HS, et al. Carcinosarcoma of the uterus: a comparison of adjuvant therapy and outcome. Asia Pac J Clin Oncol. 2006;2:57-63. (Pubitemid 43329481)
19. Wong L, See HT, Khoo-Tan HS, et al. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer. 2006;16: 1364-1369. (Pubitemid 43886770)
20. Yoshinaga M, Togami S, Tsuji T, et al. Clinical outcome of metastatic uterine leiomyosarcoma and carcinosarcoma in a single institute. J Obstet Gynaecol Res. 2007;33:818-822. (Pubitemid 350086514)
21. Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008; 199:536.e1-536.e8.
22. Clayton Smith D, Kenneth Macdonald O, Gaffney DK, et al. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol. 2008;88:227-232.
23. Hoskins PJ, Le N, Ellard S, et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol. 2008;108:58-62. (Pubitemid 350299420)
24. Makker V, Abu-Rustum NR, Alektiar KM, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008;111:249-254.
25. Wu TI, Hsu KH, Huang HJ, et al. Prognostic factors and adjuvant therapy in uterine carcinosarcoma. Eur J Gynaecol Oncol. 2008;29:483-488.
26. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808-818.
27. [Erratum appears in Eur J Cancer. 2008;44:1612].
28. Omura GA, Major FJ, Blessing JA. A randomized study of Adriamycin with and without dimethyl triazeoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626-632. (Pubitemid 13025913)
29. SuttonG, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamidewith orwithout cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol. 2000;79:147-153.
30. Sutton G, Blessing J, Hanjani P, et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic oncology Group study. Gynecol Oncol. 2005;96:749-752. (Pubitemid 40255496)
31. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) versus cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177-185. (Pubitemid 47575740)
32. Miller BE, Blessing JA, Stehman FB, et al. A phase II evaluation of weekly gemcitabine and docetaxel for secondline treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2010;118: 139-144.